The Division of Research is pleased to announce the approval of a new indirect cost rate for clinical trials. The rate of 31% will be applied to new studies beginning on or after February 1, 2019.
A clinical trial is defined as controlled, clinical testing in human subjects of investigational new drugs, devices, treatments, or diagnostics, or comparisons of approved drugs, devices, treatments, or diagnostics, to assess their safety, efficacy, benefits, costs, adverse reactions, and/or outcomes.
This new rate is only applicable to projects funded by private sponsors; government-funded projects must use one of the current, negotiated IDC rates.
If you have any questions, please contact your assigned pre-award research administrator or Benjamin Mull, associate director, in the Office of Contracts & Grants.